<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3057">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829552</url>
  </required_header>
  <id_info>
    <org_study_id>2020-219</org_study_id>
    <nct_id>NCT04829552</nct_id>
  </id_info>
  <brief_title>Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units</brief_title>
  <official_title>Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units: A Multicenter Retrospective Cohort Study in the Beaumont Healthcare System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation&#xD;
      (High dose group) improves inpatient mortality in severely ill patients with COVID-19&#xD;
      compared to prophylactic dose anticoagulation (Low dose group). The study involved 704&#xD;
      individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th,&#xD;
      2020.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">April 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inpatient all-cause mortality</measure>
    <time_frame>During hospitalization, up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of major bleeding events</measure>
    <time_frame>During hospitalization, up to 6 months</time_frame>
    <description>as defined by the International Society on Thrombosis and Hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of venous thromboses</measure>
    <time_frame>During hospitalization, up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit/Step down unit length of stay</measure>
    <time_frame>During hospitalization, up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">704</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control group: low dose group.</arm_group_label>
    <description>patients treated with subcutaneous low molecular weight heparin 40 mg once daily or unfractionated heparin 5000 IU twice or three times daily for at least 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group: high dose group.</arm_group_label>
    <description>Patients treated with subcutaneous low molecular weight heparin 1 mg/kg twice daily or 1.5 mg/kg daily or a continuous intravenous infusion of unfractionated heparin for at least 5 days.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients who were admitted to Beaumont Health System (Michigan, USA) ICU/SDU in the&#xD;
        period of March 10th to April 15th, 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  positive reverse transcription-polymerase chain reaction (rRT-PCR) test for the&#xD;
             qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory&#xD;
             specimens.&#xD;
&#xD;
          -  Intensive care unit (ICU) patient or Step-down unit (SDU) patient on invasive&#xD;
             mechanical ventilation, BiPAP, 100% non-rebreather mask, or high flow oxygen or&#xD;
             supplemental oxygen of at least 4 liters per minute nasal cannula.&#xD;
&#xD;
          -  peak d-dimer levels exceeding 1,000 mcg/mL at any time during admission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospital length of stay less than 5 days.&#xD;
&#xD;
          -  Hemorrhage before ICU/SDU admission.&#xD;
&#xD;
          -  Treatment with an anticoagulant other than low molecular weight heparin or&#xD;
             unfractionated heparin.&#xD;
&#xD;
          -  Constant treatment with the same dose of anticoagulant for less than 5 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beaumont Health System (BHS)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Faisal Musa, MD</investigator_full_name>
    <investigator_title>Staff Physician</investigator_title>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>COVID19</keyword>
  <keyword>thrombosis</keyword>
  <keyword>heparin</keyword>
  <keyword>coagulopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

